The Liver Health Initiative | SAP Partner

In this guest editorial, the author talks about the challenges associated with dealing with both health issues.

Organizations look at an agent-based model to assess the impact of vaccination, screening, and treatment on incidence and prevalence of HBV in Ontario, Canada.

The Liver Health Initiative applauds Washington, D.C. Medicaid for lifting prior authorizations that have historically restricted marginalized communities from receiving access to hepatitis treatment. Eliminating these barriers is a monumental win for health care equity and justice. We also highly encourage jurisdictional leaders to advocate for increased promotion of liver health education, to help unidentified patients understand their risk status, seek testing, and initiate treatment.

The Liver Home, a new patient-centered liver disease care model, is being introduced by Yale Medicine, Yale New Haven Health System Digestive Health Service Line.

WHO and CDC have laid out some ambitious goals for the treatment of hepatitis C, and HCV co-discoverer and vaccine developer Michael Houghton, PhD, offers some insights and commentary on whether he feels it is realistic to consider the eradication of this stubborn and subtle virus.

The Liver Health Initiative’s Thelma King Thiel, and HCV co-discoverer and vaccine developer Michael Houghton, PhD, are a “Dynamic Duo” that are working together to bring about an end to this virus.

Nobel Prize Laureate Michael Houghton, PhD, discusses the arduous journey to find the virus and a subsequent investigational vaccine designed to prevent hepatitis C (HCV).

Liver health education seems to be absent from the final draft of the National Academy of Science's Strategy for Eliminating Viral Hepatitis B & C.

Elimination of viral hepatitis depends on individuals actively participating in their own healthcare and management. They can only do this if they understand why and how to protect their miraculous, life-sustaining liver from harm. Education is the key to prevention.